SUPERIOR PLATFORM FOR STRUCTURE-BASED DRUG DESIGN
OUR DRUG DISCOVERY ENGINE IS DELIVERING AN EXPANDING PIPELINE OF NOVEL GPCR MODULATORS
OUR TEAM IS COMPOSED OF TALENTED BIOPHARMACEUTICAL PROFESSIONALS AND EXPERT SCIENTISTS
Stabilize. Target. Discover. Transform.
Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible drug targets.
Confo has attracted an international team of accomplished scientists and business professionals to deploy its innovative drug discovery platform on high value GPCR targets. With these valuable resources in place, Confo’s mission is to build a pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying treatments.
“At Confo, our multi-faceted approach to building value starts from our outstanding technology, our stellar team and a growing proprietary pipeline of novel drug candidates. We further validate our approach through strategic partnerships with industry leaders and a strong consortium of global investors.”
Ghent, Belgium – September 12, 2023 – Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), today announced the appointment of Stephen Dowd, PhD, MBA, to its executive team as Chief Business Officer (CBO). “We are thrilled to welcome Stephen to Confo and believe his considerable experience will make him an
Ghent, Belgium – August 29, 2023 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced the appointment of Dieter Weinand as Independent Chairman of its Board of Directors. Mr. Weinand brings with him a wealth of experience with more than 35 years in the pharmaceutical industry and over 25 years as the
Collaboration to make use of Confo’s unique suite of ConfoBody®-enabled antibody discovery technologies on two GPCR targets Confo to receive upfront and milestone payments Tiered royalties payable to Confo on net sales from resulting products Ghent, Belgium – June 15, 2023 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.